RNS Number : 9328P
ReNeuron Group plc
15 February 2023
 

ReNeuron Group plc

("ReNeuron" or "the Company" or "the Group")

 

Grant of Options

 

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that grants were made on 14 February 2023 for options over 4,030,000 Ordinary Shares of 1p each ("Options") under the terms of the Company's Long Term Incentive Plan ("The Plan") and its Non-Executive Share Option Scheme.  The grants of 3,000,000 Options made to Directors and Persons Discharging Managerial Responsibilities (PDMRs) are set out further in the table below.

 

1,615,000 of the Options granted under The Plan have an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days.

 

The remaining 1,415,000 of the Options granted under The Plan have an exercise price of 31.5 pence per share. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. None of these Options are subject to any further performance conditions.

 

The 1,000,000 Options granted to Iain Ross are granted under the Non-Executive Share Option Scheme. 750,000 of the Options are granted with an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days. 250,000 of the Options are granted with an exercise price of 50.0 pence per share without any further performance conditions. All of Mr Ross's options vest monthly over three years on a straight-line basis.

 

 

Name

Title

Date of grant of Options

Number of Options granted

 

Total shares over which options are held (post award)

Percentage of issued shares under option

Iain Ross

Executive Chairman

14 February 2023

1,000,000

1,500,000

2.62%

John Hawkins

Chief Financial Officer

14 February 2023

500,000

840,000

1.47%

Randolph Corteling

Chief Scientific Officer

14 February 2023

500,000

1,000,000

1.75%

Simon Dew

Chief Business Officer

14 February 2023

600,000

600,000

1.05%

Suzanne Hancock

Chief Operations Officer

14 February 2023

400,000

749,326

1.31%

 

 

                                                                                                                ENDS

 

 

 

Enquiries:

 

ReNeuron

www.reneuron.com/investors

Iain Ross, Chairman

Via Walbrook PR

John Hawkins, Chief Financial Officer




Liberum Capital Limited (NOMAD and Joint Broker)

Phil Walker (Investment Banking)

Richard Lindley (Investment Banking)

Ben Cryer (Investment Banking)

+44 (0)20 3100 2000

 



Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus / Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

 



 

About ReNeuron

 

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

(Disclosure in relation to grant of share options to Directors and PDMRs)

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Iain Ross

2

Reason for the notification 

a)

Position/status 

Executive Chairman

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

0.00

1,000,000



d)

 

Aggregated information 

N/A

e)

Date of the transaction 

14 February 2023

f)

Place of the transaction 

Outside of a trading venue

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Hawkins

2

Reason for the notification 

a)

Position/status 

Chief Financial Officer

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

0.00

 

500,000



d)

 

Aggregated information 

N/A

e)

Date of the transaction 

14 February 2023

f)

Place of the transaction 

Outside of a trading venue

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Randolph Corteling

2

Reason for the notification 

a)

Position/status 

Chief Scientific Officer

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

0.00

 

500,000



d)

 

Aggregated information 

N/A

e)

Date of the transaction 

14 February 2023

f)

Place of the transaction 

Outside of a trading venue

 

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Simon Dew

2

Reason for the notification 

a)

Position/status 

Chief Business Officer

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

0.00

 

600,000



d)

 

Aggregated information 

N/A

e)

Date of the transaction 

14 February 2023

f)

Place of the transaction 

Outside of a trading venue

 

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Suzanne Hancock

2

Reason for the notification 

a)

Position/status 

Head of Operations

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Grant of share options

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

0.00

 

400,000



d)

 

Aggregated information 

N/A

e)

Date of the transaction 

14 February 2023

f)

Place of the transaction 

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKZLFFXLLZBBD